Gsk (GSK) Assets Average (2009 - 2026)
Gsk (GSK) posted quarterly Assets Average of $83.8 billion for Q2 2026, up 7.77% year-over-year from $77.8 billion in Q2 2025, and up 0.92% quarter-over-quarter from $83.0 billion in Q1 2026.
Gsk (GSK) Assets Average (2009 - 2026) Analysis & Trends
Gsk's Assets Average history runs 18 years deep, the most recent figure standing at $83.8 billion for Q2 2026.
- In Q2 2026, Assets Average rose 7.77% year-over-year to $83.8 billion; the TTM figure through Jun 2026 stood at $83.8 billion (up 7.77% YoY), while the FY2025 annual figure was $78.3 billion, up 4.81% from the prior year.
- Assets Average for Q2 2026 stood at $83.8 billion, up from $83.0 billion in the prior quarter.
- The five-year high for Assets Average was $91.6 billion in Q3 2022, with the low at $70.8 billion in Q4 2022.
- The 5-year median for Assets Average is $76.1 billion (2024), against an average of $78.2 billion.
- The sharpest annual moves came in 2022 and 2025: Assets Average slumped 34.16% in 2022, then increased 8.81% in 2025.
- Gsk's Assets Average stood at $70.8 billion in 2022, then climbed by 6.14% to $75.2 billion in 2023, then gained by 0.94% to $75.9 billion in 2024, then increased by 8.12% to $82.0 billion in 2025, then rose by 2.15% to $83.8 billion in 2026.
- Business Quant data shows GSK's Assets Average at $83.8 billion in Q2 2026, $83.0 billion in Q1 2026, and $82.0 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 200.98 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 135.79 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 129.24 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 114.92 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 94.07 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 52.82 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 204.57 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 83.80 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 149.95 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 83.80 Bn |
| Mar 31, 2026 | 83.03 Bn |
| Dec 31, 2025 | 82.03 Bn |
| Sep 30, 2025 | 80.91 Bn |
| Jun 30, 2025 | 77.76 Bn |
| Mar 31, 2025 | 76.39 Bn |
| Dec 31, 2024 | 75.87 Bn |
| Sep 30, 2024 | 74.36 Bn |
| Jun 30, 2024 | 73.76 Bn |
| Mar 31, 2024 | 73.73 Bn |
| Dec 31, 2023 | 75.16 Bn |
| Sep 30, 2023 | 75.75 Bn |
| Jun 30, 2023 | 72.82 Bn |
| Mar 31, 2023 | 70.89 Bn |
| Dec 31, 2022 | 70.81 Bn |
| Sep 30, 2022 | 91.61 Bn |
| Jun 30, 2022 | 86.27 Bn |
| Mar 31, 2022 | 83.52 Bn |
| Dec 31, 2021 | 107.56 Bn |
| Sep 30, 2021 | 108.06 Bn |